Cover Image

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma. In glioblastoma, promoter methylation of the counteracting DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) correlates with survival of patients ex...

Full description

Saved in:
Bibliographic Details
Main Authors: Hassel, Jessica C. (Author) , Sucker, Antje (Author) , Edler, Lutz (Author) , Kurzen, Hjalmar (Author) , Moll, I. (Author) , Stresemann, C. (Author) , Spieth, K. (Author) , Mauch, C. (Author) , Rass, K. (Author) , Dummer, R. (Author) , Schadendorf, Dirk (Author)
Format: Article (Journal)
Language:English
Published: 24 August 2010
In: British journal of cancer
Year: 2010, Volume: 103, Issue: 6, Pages: 820-826
ISSN:1532-1827
DOI:10.1038/sj.bjc.6605796
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bjc.6605796
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/6605796
Get full text
Author Notes:J.C. Hassel, A. Sucker, L. Edler, H. Kurzen, I. Moll, C. Stresemann, K. Spieth, C. Mauch, K. Rass, R. Dummer and D. Schadendorf on behalf of DeCOG
Description
Summary:Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma. In glioblastoma, promoter methylation of the counteracting DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) correlates with survival of patients exposed to TMZ in combination with radiotherapy. For melanoma, data are limited and controversial.
Item Description:Gesehen am 27.03.2023
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/sj.bjc.6605796

Similar Items